Literature DB >> 18850119

A novel mutation in the MFSD8 gene in late infantile neuronal ceroid lipofuscinosis.

E Stogmann1, S El Tawil, J Wagenstaller, A Gaber, S Edris, A Abdelhady, E Assem-Hilger, F Leutmezer, S Bonelli, C Baumgartner, F Zimprich, T M Strom, A Zimprich.   

Abstract

Neuronal ceroid lipofuscinoses (NCL) are lysosomal storage disorders and constitute the most common group of progressive neurodegenerative diseases in childhood. Most NCLs are inherited in a recessive manner and are clinically characterised by a variable age at onset, epileptic seizures, psychomotor decline, visual impairment and premature death. To date, eight causative genes have been identified to underlie various clinical forms of NCL. We performed a genome-wide linkage analysis followed by sequencing the recently described NCL gene MFSD8 in three affected and three unaffected members of a consanguineous Egyptian family with an autosomal recessively inherited progressive neurodegenerative disorder. The clinical picture of the patients was compatible with a late infantile NCL (LINCL); however, impairment of the visual system was not a cardinal symptom in the respective family. By linkage analysis, we identified two putative loci on chromosome 1p36.11-p35.1 and 4q28.1-q28.2. The latter locus (4q28.1-q28.2) contained the MFSD8 gene, comprising a novel homozygous missense mutation in exon 5 (c.362a>g /p.Tyr121Cys), which segregated with the disease in the three affected sibs. We describe a novel mutation in the previously identified MFSD8 gene in a family with a common phenotype of LINCL, but no clinical report of vision loss. Our results enlarge the mutational and perhaps the nosological spectrum of one of the recently identified subtypes of NCL, called CLN7.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18850119     DOI: 10.1007/s10048-008-0153-1

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  17 in total

1.  Allegro, a new computer program for multipoint linkage analysis.

Authors:  D F Gudbjartsson; K Jonasson; M L Frigge; A Kong
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

Review 2.  Neuronal ceroid lipofuscinoses in childhood.

Authors:  P Santavuori; L Lauronen; K Kirveskari; L Aberg; K Sainio
Journal:  Suppl Clin Neurophysiol       Date:  2000

3.  Neuronal ceroid lipofuscinoses (NCL).

Authors:  Sara E Mole
Journal:  Eur J Paediatr Neurol       Date:  2006-10-10       Impact factor: 3.140

Review 4.  Molecular genetics of the NCLs -- status and perspectives.

Authors:  Eija Siintola; Anna-Elina Lehesjoki; Sara E Mole
Journal:  Biochim Biophys Acta       Date:  2006-05-27

5.  Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.

Authors:  Robert Steinfeld; Peter Heim; Henning von Gregory; Kerstin Meyer; Kurt Ullrich; Hans H Goebel; Alfried Kohlschütter
Journal:  Am J Med Genet       Date:  2002-11-01

Review 6.  Pheno/genotypic correlations of neuronal ceroid lipofuscinoses.

Authors:  K E Wisniewski; N Zhong; M Philippart
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

7.  Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Michael Chang; Jonathan D Cooper; David E Sleat; Seng H Cheng; James C Dodge; Marco A Passini; Peter Lobel; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-02-12       Impact factor: 11.454

Review 8.  Current state of clinical and morphological features in human NCL.

Authors:  Hans H Goebel; Krystyna E Wisniewski
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

Review 9.  The genetic spectrum of human neuronal ceroid-lipofuscinoses.

Authors:  Sara E Mole
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

10.  Heterogeneity of late-infantile neuronal ceroid lipofuscinosis.

Authors:  N Zhong; D N Moroziewicz; W Ju; A Jurkiewicz; L Johnston; K E Wisniewski; W T Brown
Journal:  Genet Med       Date:  2000 Nov-Dec       Impact factor: 8.822

View more
  11 in total

Review 1.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

2.  Expression and lysosomal targeting of CLN7, a major facilitator superfamily transporter associated with variant late-infantile neuronal ceroid lipofuscinosis.

Authors:  A Sharifi; M Kousi; C Sagné; G C Bellenchi; L Morel; M Darmon; H Hulková; R Ruivo; C Debacker; S El Mestikawy; M Elleder; A-E Lehesjoki; A Jalanko; B Gasnier; A Kyttälä
Journal:  Hum Mol Genet       Date:  2010-09-07       Impact factor: 6.150

3.  Neuronal ceroid lipofuscinosis caused by MFSD8 mutations: a common theme emerging.

Authors:  M A Aldahmesh; Z N Al-Hassnan; M Aldosari; F S Alkuraya
Journal:  Neurogenetics       Date:  2009-03-10       Impact factor: 2.660

4.  Novel in-frame deletion in MFSD8 gene revealed by trio whole exome sequencing in an Iranian affected with neuronal ceroid lipofuscinosis type 7: a case report.

Authors:  Ali Hosseini Bereshneh; Masoud Garshasbi
Journal:  J Med Case Rep       Date:  2018-09-25

5.  A rare homozygous MFSD8 single-base-pair deletion and frameshift in the whole genome sequence of a Chinese Crested dog with neuronal ceroid lipofuscinosis.

Authors:  Juyuan Guo; Dennis P O'Brien; Tendai Mhlanga-Mutangadura; Natasha J Olby; Jeremy F Taylor; Robert D Schnabel; Martin L Katz; Gary S Johnson
Journal:  BMC Vet Res       Date:  2015-01-03       Impact factor: 2.741

6.  Loss of CLN7 results in depletion of soluble lysosomal proteins and impaired mTOR reactivation.

Authors:  Tatyana Danyukova; Khandsuren Ariunbat; Melanie Thelen; Nahal Brocke-Ahmadinejad; Sara E Mole; Stephan Storch
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

7.  AAV9/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease.

Authors:  Xin Chen; Thomas Dong; Yuhui Hu; Frances C Shaffo; Nandkishore R Belur; Joseph R Mazzulli; Steven J Gray
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

8.  CLN7/MFSD8 may be an important factor for SARS-CoV-2 cell entry.

Authors:  Elena-Sofia Heinl; Sebastian Lorenz; Barbara Schmidt; Nouf Nasser M Laqtom; Joseph R Mazzulli; Laetitia Francelle; Timothy W Yu; Benjamin Greenberg; Stephan Storch; Ines Tegtmeier; Helga Othmen; Katja Maurer; Malin Steinfurth; Ralph Witzgall; Vladimir Milenkovic; Christian H Wetzel; Markus Reichold
Journal:  iScience       Date:  2022-09-06

Review 9.  Drosophila melanogaster as a model organism of brain diseases.

Authors:  Astrid Jeibmann; Werner Paulus
Journal:  Int J Mol Sci       Date:  2009-02-02       Impact factor: 6.208

10.  A novel MFSD8 mutation in a Russian patient with neuronal ceroid lipofuscinosis type 7: a case report.

Authors:  Anastasiya Aleksandrovna Kozina; Elena Grigorievna Okuneva; Natalia Vladimirovna Baryshnikova; Anna Yurievna Krasnenko; Kirill Yurievich Tsukanov; Olesya Igorevna Klimchuk; Olga Borisovna Kondakova; Anna Nikolaevna Larionova; Tatyana Timofeevna Batysheva; Ekaterina Ivanovna Surkova; Peter Alekseevich Shatalov; Valery Vladimirovich Ilinsky
Journal:  BMC Med Genet       Date:  2018-08-25       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.